|MDACC Study No:||2013-0161 (clinicaltrials.gov NCT No: NCT02013167)|
|Title:||A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)|
|Principal Investigator:||Hagop Kantarjian|
|Study Description:||The goal of this clinical research study is to learn if and how long |
blinatumomab may be able to help control B-precursor, relapsed or refractory
Ph- ALL compared to standard-of-care chemotherapy treatments. The safety of
blinatumomab will also be compared to standard-of-care chemotherapy.